# argenx SE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/argenx-se

- Industry: Pharmaceuticals
- Headquarters: Breda, Netherlands
- Website: www.argenx.com
- Total disclosed funding: $62M
- Latest round: Series B (Nov 4, 2013)
- Investors on record: 11

## About

argenx SE is a biotechnology company specializing in the development of innovative immunology therapies targeting severe autoimmune diseases, providing advanced treatment options for patients in need.Founded in 2008 in Breda, Netherlands, argenx SE focuses on creating therapies for severe autoimmune diseases. Led by CEO Tim Van Hauwermeiren, the company has successfully raised USD 700.00 mn through various funding rounds, with its most recent funding round being a Private Placement on February 2, 2021, where it raised USD 700.00 mn, bringing the total amount raised to USD 700.00 mn. The company has completed a total of 17 deals to date.argenx specializes in the development of innovative immunology therapies, particularly focusing on severe autoimmune diseases. The company’s core product, efgartigimod, is FDA approved and marketed under the names VYVGART and VYVGART Hytrulo, specifically for treating generalized myasthenia gravis. This therapy functions by blocking the neonatal Fc receptor (FcRn), thereby reducing pathogenic immunoglobulin G (IgG) antibodies. Another significant product in their pipeline is ARGX-117, which targets the complement component C2 to address severe IgM-driven autoimmune diseases. argenx serves a diverse client base that includes healthcare professionals and institutions primarily in the United States and European markets, demonstrating a commitment to translating immunology breakthroughs into effective treatments.In 2023, argenx reported revenue of USD 1.23 bn, primarily generated through the sales of its flagship product, efgartigimod, which is offered to healthcare providers and institutions. Revenue is driven by the demand for their innovative treatments for severe autoimmune conditions, reflecting the value delivered to both patients and healthcare systems, while the company's sales structure typically follows a B2B model, ensuring streamlined purchasing processes through negotiated contracts with healthcare providers.Looking ahead, argenx SE plans to utilize the funds raised in its recent Private Placement to accelerate the preclinical program for ARGX-113 towards clinical development. The company is also focused on expanding its market presence in the United States and Europe, aiming to strengthen its pipeline and bring new products to market. With ongoing clinical trials and strategic initiatives, argenx is well-positioned to enhance its therapeutic offerings and enter new geographic regions, supporting its growth strategy.

## Funding rounds

- Series B, Nov 4, 2013, $6.7M — PMV
- Series B, Dec 1, 2011, $37M — OrbiMed Advisors, Seventure Partners, EQT Life Sciences, Omnes Capital, Forbion, BioGeneration Ventures, Thuja Capital, Erasmus MC Biomedical Fund, VIB
- Series A, Dec 3, 2009, $4.5M — Omnes Capital, VIB
- Series A, Sep 10, 2009, $14M — EQT Life Sciences, KBC Private Equity, Forbion, BioGeneration Ventures, Thuja Capital, Erasmus MC Biomedical Fund

## Investors

- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B
- KBC Private Equity (https://capitalatlas.ai/funds/kbc-private-equity) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A, Series B
- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Series A, Series B
- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Series A, Series B
- Erasmus MC Biomedical Fund (https://capitalatlas.ai/funds/erasmus-mc-biomedical-fund) — Series A, Series B
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A, Series B
- VIB — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series B
- PMV (https://capitalatlas.ai/funds/pmv) — Series B